C3L-02552
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 68.75838467
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.640
- COAGULATION+0.500
- HYPOXIA+0.430
- MYOGENESIS+0.430
- UV_RESPONSE_DN+0.430
- HEDGEHOG_SIGNALING+0.410
- APICAL_JUNCTION+0.400
- IL2_STAT5_SIGNALING+0.400
- NOTCH_SIGNALING+0.390
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V2-0.450
- MYC_TARGETS_V1-0.340
- SPERMATOGENESIS-0.240
- MTORC1_SIGNALING-0.230
- DNA_REPAIR-0.200
- MITOTIC_SPINDLE-0.150
- PROTEIN_SECRETION-0.120
- PI3K_AKT_MTOR_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617877 | — | A | 0.941 |
| 2 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.938 |
| 3 | MBCProject_0734_T1A_RNA | — | A | 0.925 |
| 4 | SRR8392884 | — | cohortA1 | 0.924 |
| 5 | TCGA-73-4658-01A-01R-1755-07 | — | cohortA1 | 0.919 |
| 6 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.916 |
| 7 | ERR2208941 | — | — | 0.915 |
| 8 | 45b4921e-fce7-41f8-bb63-ed98343ceec8 | — | — | 0.913 |
| 9 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.912 |
| 10 | TCGA-BH-A0DI-01A-21R-A12P-07 | — | A | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.640 | Remibrutinib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| HYPOXIA | 0.430 | Idelalisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |